The European Medicines Agency has agreed to review UCB’s applications seeking the approval of bimekizumab for adults with…
Steve Bryson PhD
Steve holds a PhD in Biochemistry from the Faculty of Medicine at the University of Toronto, Canada. He worked as a medical scientist for 18 years, within both industry and academia, where his research focused on the discovery of new medicines to treat inflammatory disorders and infectious diseases. Steve recently stepped away from the lab and into science communications, where he’s helping make medical science information more accessible for everyone.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Steve Bryson PhD
Ankylosing spondylitis (AS) led to bone formation that resulted in the rare complete fusion of ankle and foot bones…
High levels of the pro-inflammatory molecule GM-CSF were found in the bloodstream of people with active ankylosing spondylitis (AS)…
Treatment with Cosentyx (secukinumab) leads to sustained reductions in symptoms of active…
Psoriasis in ankylosing spondylitis (AS) patients is not related to axial…
Anti-TNF therapies can halt disease progression and bone loss, and are associated with clinical improvement in…